<br>        Inclusion criteria:<br><br>          1. Age >= 40 years;<br><br>          2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European<br>             Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic<br>             Association (ALAT) IPF guideline for diagnosis and management, within 5 years;<br><br>          3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if<br>             available surgical lung biopsy pattern, as assessed by central reviewers, are<br>             consistent with diagnosis of IPF<br><br>          4. Dlco (corrected for Hb): 30%-79% predicted of normal;<br><br>          5. FVC>= 50% predicted of normal<br><br>        Exclusion criteria:<br><br>          1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit<br>             of Normal (ULN)<br><br>          2. Bilirubin > 1.5 x ULN;<br><br>          3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);<br><br>          4. Patient likely to have lung transplantation during study (being on transplantation<br>             list is acceptable for participation);<br><br>          5. Myocardial infarction within 6 months;<br><br>          6. Unstable angina within 1 month;<br><br>          7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic<br>             anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event<br>             within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or<br>             ulcers or major injury or surgery within 3 months);<br><br>          8. Thrombotic risk (inherited predisposition; history of thrombotic event (including<br>             stroke and transient ischemic attacks) within 12 months;<br><br>          9. International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and<br>             partial thromboplastin time (PTT) by > 50% of institutional ULN);<br><br>         10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit<br>             1;<br><br>         11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of<br>             visit 1;<br>      ;<br>        Inclusion criteria:<br><br>          1. Age >= 40 years;<br><br>          2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European<br>             Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic<br>             Association (ALAT) IPF guideline for diagnosis and management, within 5 years;<br><br>          3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if<br>             available surgical lung biopsy pattern, as assessed by central reviewers, are<br>             consistent with diagnosis of IPF<br><br>          4. Dlco (corrected for Hb): 30%-79% predicted of normal;<br><br>          5. FVC>= 50% predicted of normal<br><br>        Exclusion criteria:<br><br>          1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit<br>             of Normal (ULN)<br><br>          2. Bilirubin > 1.5 x ULN;<br><br>          3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);<br><br>          4. Patient likely to have lung transplantation during study (being on transplantation<br>             list is acceptable for participation);<br><br>          5. Myocardial infarction within 6 months;<br><br>          6. Unstable angina within 1 month;<br><br>          7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic<br>             anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event<br>             within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or<br>             ulcers or major injury or surgery within 3 months);<br><br>          8. Thrombotic risk (inherited predisposition; history of thrombotic event (including<br>             stroke and transient ischemic attacks) within 12 months;<br><br>          9. International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and<br>             partial thromboplastin time (PTT) by > 50% of institutional ULN);<br><br>         10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit<br>             1;<br><br>         11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of<br>             visit 1;<br>      ;<br>        Inclusion criteria:<br><br>          1. Age >= 40 years;<br><br>          2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European<br>             Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic<br>             Association (ALAT) IPF guideline for diagnosis and management, within 5 years;<br><br>          3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if<br>             available surgical lung biopsy pattern, as assessed by central reviewers, are<br>             consistent with diagnosis of IPF<br><br>          4. Dlco (corrected for Hb): 30%-79% predicted of normal;<br><br>          5. FVC>= 50% predicted of normal<br><br>        Exclusion criteria:<br><br>          1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit<br>             of Normal (ULN)<br><br>          2. Bilirubin > 1.5 x ULN;<br><br>          3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);<br><br>          4. Patient likely to have lung transplantation during study (being on transplantation<br>             list is acceptable for participation);<br><br>          5. Myocardial infarction within 6 months;<br><br>          6. Unstable angina within 1 month;<br><br>          7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic<br>             anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event<br>             within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or<br>             ulcers or major injury or surgery within 3 months);<br><br>          8. Thrombotic risk (inherited predisposition; history of thrombotic event (including<br>             stroke and transient ischemic attacks) within 12 months;<br><br>          9. International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and<br>             partial thromboplastin time (PTT) by > 50% of institutional ULN);<br><br>         10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit<br>             1;<br><br>         11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of<br>             visit 1;<br>      ;<br>        Inclusion criteria:<br><br>          1. Age >= 40 years;<br><br>          2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European<br>             Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic<br>             Association (ALAT) IPF guideline for diagnosis and management, within 5 years;<br><br>          3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if<br>             available surgical lung biopsy pattern, as assessed by central reviewers, are<br>             consistent with diagnosis of IPF<br><br>          4. Dlco (corrected for Hb): 30%-79% predicted of normal;<br><br>          5. FVC>= 50% predicted of normal<br><br>        Exclusion criteria:<br><br>          1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit<br>             of Normal (ULN)<br><br>          2. Bilirubin > 1.5 x ULN;<br><br>          3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);<br><br>          4. Patient likely to have lung transplantation during study (being on transplantation<br>             list is acceptable for participation);<br><br>          5. Myocardial infarction within 6 months;<br><br>          6. Unstable angina within 1 month;<br><br>          7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic<br>             anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event<br>             within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or<br>             ulcers or major injury or surgery within 3 months);<br><br>          8. Thrombotic risk (inherited predisposition; history of thrombotic event (including<br>             stroke and transient ischemic attacks) within 12 months;<br><br>          9. International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and<br>             partial thromboplastin time (PTT) by > 50% of institutional ULN);<br><br>         10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit<br>             1;<br><br>         11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of<br>             visit 1;<br>